BRDT

BRDT (bromodomain testis-specific protein) is a testis-specific member of the BET (bromodomain and extra-terminal) family that functions as an epigenetic reader of acetylated histones and regulates transcriptional programs required for male germ-cell differentiation^[1][2]. BRDT contains two bromodomains, and its first bromodomain (BD1) recognizes hyperacetylated histone H4, enabling stable chromatin association and directing chromatin remodeling during spermatogenesis^[1][2]. Mechanistically, BRDT coordinates stage-specific gene expression from meiosis through post-meiotic differentiation and links histone acetylation signals to large-scale genome reorganization in developing male germ cells^[2]. During spermiogenesis, BRDT promotes genome-wide histone replacement and chromatin compaction, processes required for proper sperm maturation and male fertility^[2]. Experimental studies further demonstrated that BRDT is essential for meiotic chromatin organization, meiotic sex chromosome inactivation, and epigenetic reprogramming during prophase I, indicating a broader role in maintaining germ-cell genome integrity^[3]. In mouse models, loss of BD1 causes severe spermiogenic defects and impaired chromatin organization, whereas complete BRDT deficiency arrests spermatogenesis before the first meiotic division and results in male sterility^[1][3]. Compared with other BET family members, BRDT displays highly restricted testicular expression, making it a distinctive regulator of spermatogenesis and an attractive experimental target for reproductive biology research^[2][3]. For experimental applications, the BET bromodomain inhibitor JQ1 suppresses BRDT-dependent chromatin binding and produces a reversible contraceptive effect in mice, establishing BRDT inhibition as a valuable model for studying non-hormonal male contraception and epigenetic regulation of germ-cell development^[4].